ATE324460T1 - Hocheffiziente, retrovirale vektoren, welche keine virale, kodierende sequenz enthalten - Google Patents

Hocheffiziente, retrovirale vektoren, welche keine virale, kodierende sequenz enthalten

Info

Publication number
ATE324460T1
ATE324460T1 AT99929919T AT99929919T ATE324460T1 AT E324460 T1 ATE324460 T1 AT E324460T1 AT 99929919 T AT99929919 T AT 99929919T AT 99929919 T AT99929919 T AT 99929919T AT E324460 T1 ATE324460 T1 AT E324460T1
Authority
AT
Austria
Prior art keywords
vectors
retroviral vectors
gene
improved
coding sequence
Prior art date
Application number
AT99929919T
Other languages
English (en)
Inventor
Sunyoung Kim
Seung Shin Yu
Jong-Mook Kim
Original Assignee
Viromed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Ltd filed Critical Viromed Ltd
Application granted granted Critical
Publication of ATE324460T1 publication Critical patent/ATE324460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99929919T 1998-06-26 1999-06-24 Hocheffiziente, retrovirale vektoren, welche keine virale, kodierende sequenz enthalten ATE324460T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980024478 1998-06-26
KR1019990023398A KR20000006334A (ko) 1998-06-26 1999-06-22 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터

Publications (1)

Publication Number Publication Date
ATE324460T1 true ATE324460T1 (de) 2006-05-15

Family

ID=36320174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929919T ATE324460T1 (de) 1998-06-26 1999-06-24 Hocheffiziente, retrovirale vektoren, welche keine virale, kodierende sequenz enthalten

Country Status (14)

Country Link
US (1) US6451595B1 (de)
EP (1) EP1032697B1 (de)
JP (1) JP3864049B2 (de)
KR (1) KR20000006334A (de)
CN (1) CN1154744C (de)
AT (1) ATE324460T1 (de)
AU (1) AU4655499A (de)
DE (1) DE69931023T2 (de)
DK (1) DK1032697T3 (de)
ES (1) ES2260918T3 (de)
ID (1) ID24192A (de)
PT (1) PT1032697E (de)
RU (1) RU2203321C2 (de)
WO (1) WO2000000629A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908788D0 (en) * 1999-04-16 1999-06-09 Univ London Gene expression in eukaryotic cells
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
KR100373821B1 (ko) 2000-09-08 2003-02-26 주식회사 바이로메드 세포에서 유래한 변형된 비코딩 서열을 갖는 개선된고효율 레트로바이러스 벡터
WO2002053191A1 (en) * 2001-01-05 2002-07-11 Viromed Limited Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
US20060019396A1 (en) * 2004-06-07 2006-01-26 Tissuegene, Inc. Retroviral vectors with enhanced efficiency of transgene expression and safety
GB2450688A (en) * 2005-05-11 2009-01-07 Viragen Inc Ovalbumin promoter constructs for retroviral vectors
US20070092490A1 (en) * 2005-10-20 2007-04-26 Kwan Hee Lee High efficiency sin vector
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP4223769A3 (de) * 2005-12-13 2023-11-01 Kyoto University Nuklearer neuprogrammierungsfaktor
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
WO2008044869A1 (en) 2006-10-10 2008-04-17 Viromed Co., Ltd. Expression vectors with improved safety
KR101390967B1 (ko) * 2006-10-10 2014-05-14 주식회사 바이로메드 안전성이 향상된 레트로바이러스 벡터
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
WO2009133971A1 (en) 2008-05-02 2009-11-05 Kyoto University Method of nuclear reprogramming
KR101242114B1 (ko) * 2010-12-30 2013-03-11 성균관대학교산학협력단 초음파 영상 기반의 유전자 전달 기술 및 리포터 유전자를 이용한 생체 내 영상에 의한 형질전환 동물의 선별 방법
WO2012157743A1 (ja) * 2011-05-19 2012-11-22 タカラバイオ株式会社 外来性ｓｄ－ｓａを有するレトロウイルスベクター
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
AU2012348558A1 (en) * 2011-12-07 2014-07-10 Glenmark Pharmaceuticals S.A. Expression cassette
CN109385437B (zh) * 2018-06-25 2020-05-26 张凤美 Dna分子、含有该dna分子的载体以及获得的永生化细胞
BR112021007334A2 (pt) 2018-10-19 2021-08-03 Cartexell Inc. anticorpo anti-l1cam ou fragmento de ligação ao antígeno do mesmo, e receptor de antígeno quimérico compreendendo o mesmo
KR20210036742A (ko) 2019-09-26 2021-04-05 주식회사 헬릭스미스 항-c-Met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도
CN113736812A (zh) * 2021-09-06 2021-12-03 武汉翼康基因科技有限公司 一种pcMINI载体及其构建方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5906817A (en) * 1993-04-21 1999-05-25 Institut Pasteur Biocompatible implant for the expression and in vivo secretion of a therapeutic substance
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU3258295A (en) * 1994-09-08 1996-03-27 Boehringer Mannheim Gmbh Retroviral vector hybrids and the use thereof for gene transfer
KR100246096B1 (ko) * 1996-09-21 2000-03-15 이선경 유전자 요법을 위한 개선된 레트로바이러스 벡터

Also Published As

Publication number Publication date
DE69931023T2 (de) 2006-11-23
JP2002519037A (ja) 2002-07-02
DK1032697T3 (da) 2006-08-14
CN1154744C (zh) 2004-06-23
PT1032697E (pt) 2006-06-30
US6451595B1 (en) 2002-09-17
AU4655499A (en) 2000-01-17
EP1032697A1 (de) 2000-09-06
EP1032697B1 (de) 2006-04-26
RU2203321C2 (ru) 2003-04-27
DE69931023D1 (de) 2006-06-01
ES2260918T3 (es) 2006-11-01
KR20000006334A (ko) 2000-01-25
CN1277636A (zh) 2000-12-20
WO2000000629A1 (en) 2000-01-06
ID24192A (id) 2000-06-13
JP3864049B2 (ja) 2006-12-27

Similar Documents

Publication Publication Date Title
ATE324460T1 (de) Hocheffiziente, retrovirale vektoren, welche keine virale, kodierende sequenz enthalten
Babij et al. Characterization of a mammalian smooth muscle myosin heavy-chain gene: complete nucleotide and protein coding sequence and analysis of the 5'end of the gene.
EP1395293B1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
AR003112A1 (es) Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas
DK0682112T3 (da) Fremgangsmåde til et opnå ekspression eller til at forbedre ekspressionsgraden af et gen
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
WO1997007225A3 (en) High efficiency retroviral packaging system
DE69033896D1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
WO1998046781A3 (en) Novel transgene expression system for increased persistence
WO2021083183A1 (zh) 一种造血干细胞hbb基因修复的方法及产品
Renbaum et al. Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene
Rabbits The c-myc photo-oncogene: Involvement in chromosomal abnormalities
DE69432988D1 (de) Für ammonium-transporter kodierende dna-sequenzen und dieser enthaltende, plasmide, bakterien, hefen und pflanzenzellen
GB2322131A (en) Improved retroviral vectors for gene therapy
Boyer et al. Position-dependent variegation of a CD4 minigene with targeted expression to mature CD4+ T cells.
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
WO1987005048A1 (en) Plasmids which inhibit human t-cell lymphotropic virus type iii replication
ATE278029T1 (de) Rekonstituierender retroviraler vektor (recon vektor) für gezielte genexpression
Hurez et al. Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction
Fray et al. Identification of unexplained DNA fragments within the T-DNA borders of the Bin 19 plant transformation vector
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
JP2006501829A (ja) Ｈｏｘで誘導される増殖を制限する遺伝子をブロックする幹細胞増殖因子およびその方法
Lavett A model for transcriptional regulation based upon homology between introns and promoter regions and secondary structure in the promoter regions: the human globins
Malik et al. Genetically engineered cures: gene therapy for sickle cell disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032697

Country of ref document: EP

REN Ceased due to non-payment of the annual fee